Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
2 September 2020Big PharmaMuireann Bolger

Gilead signs deal to license new cancer treatment

Gilead Sciences has unveiled an agreement with Jounce Therapeutics to exclusively develop and license its antibody programme, JTX-1811, which is designed to fight cancer cells.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead secures new anti-cancer therapy in $4.9bn deal
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Gilead secures new anti-cancer therapy in $4.9bn deal
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.

More on this story

Americas
Gilead secures new anti-cancer therapy in $4.9bn deal
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court